Göcze P, Vahrson H
Pécsi Orvostudományi Egyetem, Szülészeti és Nögyógyászati Klinika.
Orv Hetil. 1993 Apr 25;134(17):915-8.
Serum concentrations of ovarian carcinoma antigen (CA 125) were determined by Abbot CA 125-EIA Monoclonal kit from 66 patients with malignant ovarian tumor. The preoperative serum levels of CA 125 were elevated (> 35.0 IU/ml) in 93% (27/29). After the laparotomy and before the irradiation or chemotherapy in 36% (24/36) of patients had elevated levels. No significant correlation was seen between elevated levels and histology, tumor grade and clinical stage. However, the rate of positive cases were significantly higher in advanced stages than in the 1st stage (p < 0.05). No significant correlation was found between the preoperative levels of CA 125 and the clinical course. The postoperative elevated levels indicated bad prognosis. Good conformity was found between CA 125 levels and the therapy response. Serological follow up revealed a correlation with the clinical course of ovarian carcinoma in 84% (44/52). In patients with tumor progression the CA 125 levels increased before clinical signs of progression with median lead time of 97 days. The second look laparotomy proved, that residual tumor larger than 2 cm of diameter cause elevated levels. Smaller tumors remained marker negatives. CA 125 determination before operation, during and after therapy provide a useful tool in detecting progression and persistence of ovarian carcinoma.
采用雅培CA 125-EIA单克隆试剂盒，对66例卵巢恶性肿瘤患者测定血清卵巢癌抗原（CA 125）浓度。术前血清CA 125水平升高（>35.0 IU/ml）的患者占93%（27/29）。剖腹手术后、放疗或化疗前，36%（24/36）的患者CA 125水平升高。CA 125水平升高与组织学、肿瘤分级及临床分期之间未见明显相关性。然而，晚期患者的阳性率显著高于Ⅰ期患者（p<0.05）。术前CA 125水平与临床病程之间未发现明显相关性。术后CA 125水平升高提示预后不良。CA 125水平与治疗反应之间具有良好的一致性。血清学随访显示，84%（44/52）的患者CA 125水平与卵巢癌临床病程相关。在肿瘤进展的患者中，CA 125水平在出现临床进展迹象之前升高，中位提前期为97天。二次剖腹探查证实，直径大于2 cm的残留肿瘤会导致CA 125水平升高。较小的肿瘤CA 125标记物仍为阴性。术前、治疗期间及治疗后测定CA 125，为检测卵巢癌的进展和持续存在提供了一种有用的手段。
